Drug class profile · refreshed daily from federal data

Beta-Adrenergic Blocker

3 molecules in this class, $1.06B combined CY2024 Part D spend across 80.7M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Beta-Adrenergic Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $1.06Bcombined across class
Total Rx claims: 80.7M24.5M unique beneficiaries
Generic mfrs (active): 57across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Metoprolol

Brand: KAPSPARGO · 72.7M Part D claims (CY24) · 22.1M beneficiaries · First FDA approval: 1993-12-23

31 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.017

→

Avg plan cost$0.137

Part D spend $853.0M 8× spread, current vs floor

Class share

80%

of class CY24 spend

View profile →

Propranolol

Brand: HEMANGEOL · 6.4M Part D claims (CY24) · 1.9M beneficiaries · First FDA approval: 1985-11-19

15 generic mfrs 0 plans require PA Active FDA shortage

Low NADAC$0.050

→

Avg plan cost$4.21

Part D spend $164.2M 84× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Bisoprolol

Brand: Bisoprolol · 1.7M Part D claims (CY24) · 547K beneficiaries · First FDA approval: 2000-11-16

11 generic mfrs 0 plans require PA

Low NADAC$0.133

→

Avg plan cost$0.214

Part D spend $44.2M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.